Real world treatment patterns and outcomes for young women with HR+/HER2- metastatic breast cancer in the United States.

Trial Profile

Real world treatment patterns and outcomes for young women with HR+/HER2- metastatic breast cancer in the United States.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Palbociclib (Primary) ; Fulvestrant; Tamoxifen
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2018 New trial record
    • 09 Dec 2017 Results assessing treatment patterns for young women with HR+/HER2- metastatic breast cancer in the United States presented at the 40th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top